12-10542, Genetic Disease Laboratory and Genetic Disease Screening Program on Clinical Laboratory Improvement Amendments (CLIA)

Investigator: Alan H. Wu, PhD
Sponsor: California Department of Public Health

Location(s): United States


The Genetic Disease Screening Program of the California Department of Public Health works to protect and improve the health of all Californians. This is  the largest screening program in the world and sets the standard in delivering high-quality, cost-effective genetic services to all Californians. The mission of the Genetic Disease Screening Program is "To serve the people of California by reducing the emotional and financial burden of disability and death caused by genetic and congenital disorders."

The Clinical Laboratory Improvement Amendments (CLIA) are federal requirements that regulate laboratory testing and require clinical laboratories to be certificated by their state as well as the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct.